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In order to form a covalent complex with DNA inside human cells, cisplatin has to overcome the protective
environment of a nucleosome, where DNA is complexed with histone proteins. Todd and Lippard (2010)
expand our understanding of this process by describing the structure of a nucleosome containing a Pt-DNA
adduct, which has important implications for more effective chemotherapeutic drug development.Many cancer chemotherapetic agents
interact with DNA inside tumor cells as
part of their mechanism of action. Intra-
cellular DNA is tightly packaged in the
form of nucleosomes and other chromatin
structures. However, this complex cellular
environment is widely ignored in cisplatin-
DNA experiments. The protein-DNA com-
plexes found in chromatin would be
expected to alter the interaction of the
drug with DNA inside cells compared
with purified DNA. As part of our growing
understanding of this process, Todd and
Lippard (2010) have investigated the inter-
action of cisplatin with a nucleosome core
at atomic resolution using X-ray crystal-
lography. They also examined the tran-
scriptional effects of a cisplatin/nucleo-
some complex.
Richmond and colleagues (Luger et al.,
1997) published the first X-ray crystal
structure of a nucleosome at atomic reso-
lution. The nucleosome consists of a
central octamer core of histone proteins
with DNA coiled around the outside of
this protein core. Electrostatic interactions
areprominent inmaintaining this complex,
with arginine residues interacting with the
minor groove of DNA as well as hydrogen
bonding observed at multiple sites
between the histones and DNA.
Cisplatin is a very successful antitumor
drug that mainly forms intrastrand cross-
links with consecutive guanine residues
in DNA. There are two main ways that
the interaction of cisplatin with nucleo-
somes can be investigated (Figure 1).
First, Pt-DNA adducts are produced and
then nucleosomes are formed on the
Pt-DNA complex. This is the process
used by Todd and Lippard (2010) in their
paper. Second, nucleosomes are formed
on a DNA sequence and then cisplatin is
reacted with the nucleosome complex.This latter strategy more closely mimics
the interaction of cisplatin with DNA inside
human cells, whereas the former strategy
can provide more detailed information at
atomic resolution.
The latter strategy has been employed
by a number of groups to investigate
cisplatin nucleosome interactions. Galea
and Murray (2002) found that cisplatin
had a 1.3-fold tendency to form adducts
in the linker region of the nucleosome
compared with the nucleosome core.
They also found that a number of cisplatin
analogs had a larger differential between
linker and core (Galea and Murray,
2010). The interaction of other antitumor
drugs with nucleosomes has also been
investigated; bleomycin is probably the
best known example. Bleomycin damage
to DNA is affected in a crucial manner by
chromatin structure, with bleomycin pref-
erentially causing single- and double-
strand breaks in the linker region of the
nucleosome.
In this issue, Todd and Lippard (2010)
have produced an X-ray crystal structure
of a 1,3-d(GpTpG) Pt adduct incorporated
into a nucleosome. Surprisingly, the Pt
adduct does not appreciably distort the
nucleosome structure. The DNA bending
caused by the Pt adduct is integrated
into the bending required by the DNA to
wrap around the histone octamer core.
The Pt adduct results in bending toward
the major groove; this is synchronous
with the nucleosomal bending at this posi-
tion in the structure. The presence of the
Pt adduct also caused directed rotational
positioning of the nucleosome core so
that the Pt adduct faces inward toward
the histone octamer core (Ober and Lip-
pard, 2007). In this protected setting, the
adduct is shielded from repair and
explains the ten-fold lower efficiency ofChemistry & Biology 17, December 22, 2010 ªrepair when the 1,3 Pt adduct is present
in a nucleosome (Wang, et al., 2003).
There are several implications from this
nucleosome work for the further develop-
ment of cisplatin analogs with clinical
potential. Cisplatin is a relatively small
molecule, and most analogs will be larger
and may not be able to sterically fit into
the nucleosome structure. It is worth
noting that carboplatin, which is the
main clinically utilized analog of cisplatin,
produces exactly the same adduct on
DNA as cisplatin. Galea and Murray
(2010) showed that increasing the size of
a cisplatin analog resulted in a reduced
ability to form adducts in the nucleosome
core. Cisplatin analogs with an attached
intercalator moiety had the largest differ-
ential between core and linker adduct
formation, probably due to the need of
the intercalator to alter the DNA structure
before Pt binding. These studies would
argue that a successful cisplatin anti-
cancer analog would have to produce
a lesion that is similar in size or identity
to that of cisplatin. Future molecular
modeling of novel cisplatin analogs bound
in a nucleosome could be highly beneficial
in the development of clinically successful
cisplatin analogs.
The 1,2 intrastrand crosslink is themost
prevalent crosslink produced by cisplatin,
and it would be exciting for Lippard and
colleagues to produce an X-ray crystal
structure of this adduct. In a previous
paper, Ober and Lippard (2008) found
that the 1,2 intrastrand Pt crosslink
produced more distortion than the 1,3
intrastrand crosslink when present in
a nucleosome and hence may result in
more restrictive structural requirements
for the 1,2 crosslink in a nucleosome.
In addition, the Pt-DNA crosslink









Figure 1. Two Procedures for Investigation of the Interaction of Cisplatin with Nucleosomal
DNA
(A) Cisplatin adducts are formed on a defined DNA sequence, an octamer of histones is added, and
a Pt-nucleosome complex is produced.
(B) A nucleosome is constructed on a defined DNA sequence, the nucleosome is treated with cisplatin,
and the Pt-DNA adducts are analyzed.
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Previewsnucleosome that had a more open struc-
ture that could more easily accommodate
a Pt crosslink. Only one DNA strand is
present at this position compared with1272 Chemistry & Biology 17, December 22,two DNA strands in the other three-quar-
ters of the nucleosome structure. It would
be interesting to investigate a Pt adduct in
a region of the nucleosome that was more2010 ª2010 Elsevier Ltd All rights reserved‘‘crowded’’ with protein-DNA interac-
tions, in order to see if sections of the
nucleosome are more accommodating
of the cisplatin adduct.
In conclusion, Todd and Lippard’s
paper is a landmark paper in our under-
standing of how cisplatin is an effective
cancer chemotherapetic agent. It appre-
ciably adds to our understanding of the
interaction of cisplatin with DNA inside
cells and has several important implica-
tions for the development of more effi-
cient cisplatin analogs.REFERENCES
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O-GlcNAcylation has now been added to the growing list of histonemodificationsmaking up themultifaceted
‘‘histone-code’’ (Sakabe et al., 2010). The sites of O-GlcNAc-histone modification hint at a role in chromatin
remodeling, thus adding to mounting evidence that O-GlcNAc cycling sits atop a robust regulatory network
maintaining higher-order chromatin structure and epigenetic memory.The hexosamine signaling pathway inte-
grates cellular nutrient stores by regu-
lating the synthesis of UDP-GlcNAc,a key metabolite required for the dynamic
O-GlcNAc modification of nuclear and
cytoplasmic proteins. Previous studieshave directly linked O-GlcNAc cycling to
signaling, transcription, and translation,
as well as to RNA and protein stability
